Can-Fite BioPharma’s (CANF) Buy Rating Reiterated at HC Wainwright

Posted by Paula Ricardo on Nov 16th, 2024

HC Wainwright reiterated their buy rating on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a report issued on Tuesday morning,Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright also issued estimates for Can-Fite BioPharma’s Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at ($0.05) EPS.

Other equities analysts have also issued research reports about the stock. StockNews.com lowered shares of Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th. EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

Check Out Our Latest Stock Analysis on CANF

Can-Fite BioPharma Price Performance

CANF opened at $1.99 on Tuesday. The stock’s 50 day moving average price is $2.25 and its 200 day moving average price is $2.52. The stock has a market cap of $7.04 million, a P/E ratio of -1.11 and a beta of 1.39. Can-Fite BioPharma has a 12 month low of $1.83 and a 12 month high of $4.69.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC grew its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.